At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
Omalizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Xolair Enhances Oral Desensitization in Peanut Allergic Patients
In Brief
A Phase 2 clinical trial evaluating Omalizumab for Peanut Allergy. Completed, enrolled 13 participants across 1 site.
Detailed Summary
This is a pilot feasibility study, using Xolair pretreatment for oral peanut desensitization.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeanut Allergy
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2011
First PostedFeb 2011
Primary CompletionSep 2013
TodayJul 2026
First PostedFeb 7, 2011
Enrollment StartFeb 1, 2011
Primary CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 15.4 years ago
Interventions
Omalizumabdrug
Omalizumab is an antibody that helps decrease allergic responses in the body